Optomed Oyj Management

Management Kriterienprüfungen 3/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Juho Himberg

Geschäftsführender

€64.0k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	81.3%
Amtszeit als Geschäftsführer	less than a year
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	5.5yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.5yrs

Jüngste Management Updates

Recent updates

Earnings Update: Here's Why Analysts Just Lifted Their Optomed Oyj (HEL:OPTOMED) Price Target To €6.63

May 11

Market Might Still Lack Some Conviction On Optomed Oyj (HEL:OPTOMED) Even After 26% Share Price Boost

May 10

Market Might Still Lack Some Conviction On Optomed Oyj (HEL:OPTOMED) Even After 25% Share Price Boost

Mar 22

Earnings Update: Optomed Oyj (HEL:OPTOMED) Just Reported And Analysts Are Trimming Their Forecasts

Feb 18

Market Cool On Optomed Oyj's (HEL:OPTOMED) Revenues

Dec 21

Is Optomed Oyj (HEL:OPTOMED) Using Debt In A Risky Way?

Nov 15

Earnings Update: Optomed Oyj (HEL:OPTOMED) Just Reported And Analysts Are Trimming Their Forecasts

Aug 09

The Optomed Oyj (HEL:OPTOMED) Share Price Has Gained 14% And Shareholders Are Hoping For More

Feb 16

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Juho Himberg im Vergleich zu den Einnahmen von Optomed Oyj verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	-€4m
Dec 31 2023	€64k	€52k	-€4m

Vergütung im Vergleich zum Markt: JuhoDie Gesamtvergütung ($USD68.72K) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Finnish ($USD330.49K).

Entschädigung vs. Einkommen: Unzureichende Daten, um die Vergütung von Juho mit der Unternehmensleistung zu vergleichen.

Geschäftsführer

Juho Himberg (54 yo)

less than a year

Amtszeit

€64,000

Vergütung

Mr. Juho Himberg is Chief Executive Officer of Optomed Oyj since October 1, 2023. He has served as the CEO of Aidian (former Orion Diagnostica), a leading point-of-care diagnostics company with innovative...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Juho Himberg	Chief Executive Officer	less than a year	€64.00k	keine Daten
Seppo Kopsala	Founder	20.5yrs	€156.00k	keine Daten
Sakari Knuutti	CFO, Chief Legal Officer & Secretary of the Board	5.5yrs	keine Daten	keine Daten

5.5yrs

Durchschnittliche Betriebszugehörigkeit

46yo

Durchschnittliches Alter

Erfahrenes Management: OPTOMEDDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (5.4 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Seppo Makinen	Independent Director	5.5yrs	€19.00k	0.062% € 66.2k
Reijo Tauriainen	Independent Director	5.5yrs	€19.00k	0.079% € 84.8k
Catherine Calarco	Independent Director	1.2yrs	€19.00k	0.012% € 13.0k
Petri Salonen	Chairman of the Board	18.5yrs	€114.00k	0.077% € 82.8k
Ty Lee	Independent Director	1.2yrs	€19.00k	0.012% € 13.0k
Anna Tenstam	Independent Director	4.1yrs	€19.00k	0.033% € 36.0k
Robert Chang	Member of International Scientific Advisory Board	3.5yrs	keine Daten	keine Daten
Nina Hautala	Member of International Scientific Advisory Board	3.5yrs	keine Daten	keine Daten
Dan Milea	Member of International Scientific Advisory Board	3.5yrs	keine Daten	keine Daten
Tunde Peto	Member of International Scientific Advisory Board	3.5yrs	keine Daten	keine Daten
Daniel Ting	Member of International Scientific Advisory Board	3.5yrs	keine Daten	keine Daten

3.5yrs

Durchschnittliche Betriebszugehörigkeit

65yo

Durchschnittliches Alter

Erfahrener Vorstand: OPTOMEDDie Vorstandsmitglieder gelten als erfahren (3.4 Jahre durchschnittliche Amtszeit).

Optomed Oyj Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Optomed Oyj Announces Nomination Board

Optomed Oyj, Annual General Meeting, May 10, 2024

Optomed Announces CEO Transition Plan

Optomed Oyj Approves Board Changes

Mars Duan Has Notifies Optomed plc That He Is Not Available for Re-Election

High number of new and inexperienced directors

Recent updates

Optomed Oyj Provides Revenue Guidance for the Full Year 2024

Earnings Update: Here's Why Analysts Just Lifted Their Optomed Oyj (HEL:OPTOMED) Price Target To €6.63

Price target increased by 14% to €6.63

Forecast to breakeven in 2026

Market Might Still Lack Some Conviction On Optomed Oyj (HEL:OPTOMED) Even After 26% Share Price Boost

First quarter 2024 earnings released: €0.064 loss per share (vs €0.076 loss in 1Q 2023)

New major risk - Share price stability

Optomed Plc Announces Optomed Aurora with AEYE Receives U.S. Food & Drug Administration Clearance in US

Optomed USA, Inc. Introduces Optomed Aurora AEYE

Market Might Still Lack Some Conviction On Optomed Oyj (HEL:OPTOMED) Even After 25% Share Price Boost

Consensus estimates of losses per share improve by 15%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 12%

Consensus revenue estimates decrease by 12%

Earnings Update: Optomed Oyj (HEL:OPTOMED) Just Reported And Analysts Are Trimming Their Forecasts

Full year 2023 earnings: EPS and revenues miss analyst expectations

Optomed Oyj Provides Revenue Guidance for the Full Year 2024

Optomed Oyj Announces Nomination Board

Market Cool On Optomed Oyj's (HEL:OPTOMED) Revenues

Is Optomed Oyj (HEL:OPTOMED) Using Debt In A Risky Way?

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Optomed Oyj Provides Revenue Guidance for the Year 2023

Forecast breakeven date moved forward to 2024

Optomed Oyj has completed a Follow-on Equity Offering in the amount of €4.290413 million.

Consensus EPS estimates fall by 15%

Earnings Update: Optomed Oyj (HEL:OPTOMED) Just Reported And Analysts Are Trimming Their Forecasts

New major risk - Share price stability

Optomed Oyj, Annual General Meeting, May 10, 2024

Forecast breakeven date pushed back to 2025

Optomed Announces CEO Transition Plan

Investors Continue Waiting On Sidelines For Optomed Oyj (HEL:OPTOMED)

Optomed Oyj Approves Board Changes

First quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Optomed Plc Provides Revenue Guidance for the Full Year 2023

Price target decreased by 9.9% to €6.37

Forecast breakeven date pushed back to 2025

Full year 2022 earnings: EPS misses analyst expectations

Optomed Oyj Provides Revenue Guidance for the Full Year of 2023

Mars Duan Has Notifies Optomed plc That He Is Not Available for Re-Election

Consensus EPS estimates fall by 12%

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Optomed Oyj Updates Earnings Guidance for the Full Year 2022

Does Optomed Oyj (HEL:OPTOMED) Have A Healthy Balance Sheet?

Optomed Oyj Announces Board Appointments

Optomed plc Elects Mars Duan to the Board of Directors

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Optomed Oyj, Annual General Meeting, May 10, 2023

Optomed Plc Announces Resignation of Xisi Guo from Board of Directors, Effective August 19, 2022

Optomed Oyj Announces Resignation of Niina Huikuri as Vice President, Marketing and Member of the Leadership Team

Optomed Oyj Announces Executive Changes

Optomed Oyj Provides Revenue Guidance for the Year 2022

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Optomed Oyj has completed a Follow-on Equity Offering in the amount of €4.822593 million.

Price target decreased to €8.45

No longer forecast to breakeven

High number of new and inexperienced directors

Is Optomed Oyj (HEL:OPTOMED) A Risky Investment?

No longer forecast to breakeven

Price target decreased to €9.95

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Optomed Oyj Provides Revenue Guidance for the Year 2022

Optomed Oyj Announces Correction in Clinical Trial Results

Optomed Oyj to Report Fiscal Year 2021 Results on Mar 04, 2022

Optomed Announces Promising Research Results with Aurora Handheld Fundus Camera

Forecast to breakeven in 2024

Third quarter 2021 earnings released: €0.062 loss per share (vs €0.031 loss in 3Q 2020)

Price target decreased to €12.70

Second quarter 2021 earnings released: €0.065 loss per share (vs €0.083 loss in 2Q 2020)